China Meheco Group Co., Ltd. Class A

China Meheco Group Co., Ltd. Class A

SSSE:600056
8.55
CNY
-0.04
(-0.47%)
0.32EPS
42.91P/E
13.28BMarket Cap
China Meheco Group Co., Ltd. Class A
SSE:600056
(Shanghai Stock Exchange)

Recent

price

8.55

P/E

ratio

42.91

div

yld

1.92%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
7.19
8.35
10.58
11.58
12.91
14.51
18.05
20.29
20.73
23.59
26.28
24.23
25.13
25.95
23.56
23.64
23.03
Revenue per Share
0.22
0.31
0.32
0.38
0.4
0.43
0.66
0.88
1.03
0.66
0.88
0.43
0.49
0.7
0.39
0.32
0.21
Basic EPS, GAAP
-0.44
0.05
0.5
-0.08
0.65
0.63
0.57
0.27
-0.17
-0.22
0.83
-0.09
0.95
0.33
0.44
0.73
- -
Free Cash Flow per Basic Share
0.07
0.04
0.12
0.22
0.19
0.17
0.17
0.21
0.3
0.37
0.32
0.37
0.26
0.25
0.35
0.2
0.16
Dividend per Share
1.67
1.94
3.54
2.68
3.51
3.81
4.61
5.25
5.67
6.01
6.69
6.86
7.23
7.73
8.04
7.91
8.04
Book Value per Share
1.49
1.73
3.11
2.37
3.2
3.49
3.93
4.56
4.32
4.6
5.29
5.44
5.88
6.31
6.6
6.49
6.34
Tangible Book Value per Share
871
871
1,281
1,281
1,383
1,417
1,437
1,496
1,496
1,496
1,496
1,496
1,496
1,496
1,496
1,496
1,496
Basic Weighted Avg Shares
6,260
7,270
13,551
14,830
17,857
20,570
25,946
30,357
31,006
35,285
39,312
36,234
37,593
38,824
35,243
35,362
34,457
Sales/Revenue/Turnover
4.55
6.33
5.51
5.25
5.14
5.54
5.82
6.83
6.64
5.9
8.46
5.66
4.36
3.91
4.26
4
3.85
Operating Margin (%)
15
18
142
144
147
170
153
197
210
223
222
275
350
431
461
499
- -
Depreciation Expense
195
269
416
485
550
614
950
1,313
1,545
981
1,311
647
736
1,048
583
473
310
Net Income, GAAP
22.42
22.66
24.08
25.79
22.88
22.87
22.19
22.7
21.96
25.85
28.01
24.02
25.72
24.29
27.21
32.49
39.79
Effective Tax Rate (%)
3.11
3.7
3.07
3.27
3.08
2.99
3.66
4.33
4.98
2.78
3.33
1.79
1.96
2.7
1.65
1.34
0.9
Profit Margin (%)
2,769
3,074
2,741
3,066
4,554
5,199
6,239
7,118
7,945
6,674
7,882
8,692
8,922
10,523
9,407
8,354
8,838
Working Capital
- -
- -
2
2
1
1
- -
1,769
554
1,122
2,065
3,146
2,436
2,768
1,741
818
1,613
LT Debt
1,609
1,936
3,471
3,873
5,482
6,039
7,926
9,139
10,172
11,011
12,218
12,509
13,171
13,888
14,326
14,364
14,567
Total Equity
14.96
18.54
11.78
9.62
10.3
11.03
14.49
15.85
15.51
9.59
8.88
4.27
5.15
6.9
3.72
3.57
- -
Return on Invested Capital (%)
8.05
11.53
10.06
9.62
9.47
8.68
10.32
10.93
11.82
6.25
8.84
4.38
4.16
5.3
2.88
2
- -
Return on Capital (%)
13.35
17.13
17.44
14.86
13.08
11.84
15.45
17.82
18.91
11.23
13.8
6.39
6.98
9.37
4.94
3.97
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
4,493
4,876
4,942
LT Borrowings
771
1,671
1,323
LT Finance Leases
273
290
290
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,496
1,496
1,496
Market Capitalization
15,363
13,089
13,283

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
28,280
29,591
29,369
Cash, Cash Equivalents & STI
2,532
3,445
3,344
Accounts Receivable, Net
15,662
15,809
15,689
Inventories
6,196
6,152
6,158
Total Current Liabilities
19,874
20,447
20,531
Payables & Accruals
- -
- -
- -
ST Debt
4,493
4,876
4,942
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.36%
3.3%
0.26%
Free Cash Flow
-187.41%
-241.2%
67.31%
Net Income, GAAP
4.99%
-11.53%
-18.77%
Sales/Revenue/Turnover
6.08%
-1.94%
0.34%
Total Cash Common Dividend
6.57%
-3.76%
-42.79%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,775
9,022
8,302
8,049
35,243
2025
8,527
8,813
- -
9,467
35,362
2026
8,189
8,763
8,037
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.12
0.08
0.06
0.39
2025
0.12
0.09
- -
0.01
0.32
2026
0.12
0.04
0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.15
0.14
0.03
0.35
2025
0.02
- -
- -
0.01
0.2
2026
0.02
0.05
0.09
- -
- -
Business
China Meheco Group Co., Ltd. (600056.SS) engages primarily in the pharmaceutical healthcare sector, operating an integrated business model spanning research and development, cultivation and processing of herbal medicines, manufacturing, distribution, logistics, international trading, academic promotion, and technical services for pharmaceuticals and medical devices; its core products encompass bulk pharmaceutical chemicals via antibiotic fermentation and chemical synthesis, tablets, injections, and capsules; antibiotics; medicines treating cardio-cerebrovascular diseases, chronic conditions, and diabetes; antiviral and anti-infectious agents; gastrointestinal drugs; non-steroidal anti-inflammatory drugs; anti-allergic agents; specialty botanicals; western medicine preparations; Chinese patent medicines and herbal pieces; medical equipment and supplies; biological products; chemical raw materials; and nutritional healthcare products, with additional operations in planting, processing, warehousing, and transporting herbs such as ginseng, licorice, ephedra, rhubarb, astragalus membranaceus, scutellaria baicalensis, and fennel. The company, founded in 1983 as China National Medicines and Health Products Import and Export Corporation and headquartered at No. 18 Guangming Zhongjie, Beijing, China, functions as the sole platform under controlling shareholder China General Technology (Group) Holding Co., Ltd. for integrating pharmaceutical and medical device manufacturing and marketing, with business segments including industrial pharmaceuticals (chemical preparations, bulk drugs, biologicals, Chinese patent medicines), commercial pharmaceuticals (wholesale and distribution of drugs and devices), and international trading (exporting natural medicines, pharmaceutical chemicals, equipment, and health products); it serves healthcare institutions, retail pharmacies, and global markets primarily in China and internationally. Recent developments feature the November 2024 agreement to acquire the remaining 40% stake in Genertec Meheco Liaoning Co., Ltd. from Li Qiang for CNY 68.4 million in cash, achieving 100% ownership upon completion subject to shareholder and board approvals, alongside ongoing strategic expansions in medicine trading via equity investments, capital increases, and industry chain integration under the Healthy China Initiative.